Please sign in to follow a disease.
Corbus Pharmaceuticals Inc.
Clinical trials sponsored by Corbus Pharmaceuticals Inc., explained in plain language.
Develops treatments for inflammatory and fibrotic diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New cancer drug CRB-701 targets Nectin-4 in advanced tumors Results expected Jan 2027 (estimated) May already have reported ↗